93
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mechanisms of human telomerase reverse transcriptase (h TERT) regulation: clinical impacts in cancer

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Limitless self-renewal is one of the hallmarks of cancer and is attained by telomere maintenance, essentially through telomerase (h TERT) activation. Transcriptional regulation of h TERT is believed to play a major role in telomerase activation in human cancers.

          Main body

          The dominant interest in telomerase results from its role in cancer. The role of telomeres and telomere maintenance mechanisms is well established as a major driving force in generating chromosomal and genomic instability. Cancer cells have acquired the ability to overcome their fate of senescence via telomere length maintenance mechanisms, mainly by telomerase activation.

          h TERT expression is up-regulated in tumors via multiple genetic and epigenetic mechanisms including h TERT amplifications, h TERT structural variants, h TERT promoter mutations and epigenetic modifications through h TERT promoter methylation. Genetic (h TERT promoter mutations) and epigenetic (h TERT promoter methylation and miRNAs) events were shown to have clinical implications in cancers that depend on h TERT activation. Knowing that telomeres are crucial for cellular self-renewal, the mechanisms responsible for telomere maintenance have a crucial role in cancer diseases and might be important oncological biomarkers. Thus, rather than quantifying TERT expression and its correlation with telomerase activation, the discovery and the assessment of the mechanisms responsible for TERT upregulation offers important information that may be used for diagnosis, prognosis, and treatment monitoring in oncology. Furthermore, a better understanding of these mechanisms may promote their translation into effective targeted cancer therapies.

          Conclusion

          Herein, we reviewed the underlying mechanisms of h TERT regulation, their role in oncogenesis, and the potential clinical applications in telomerase-dependent cancers.

          Related collections

          Most cited references195

          • Record: found
          • Abstract: found
          • Article: found

          Hallmarks of Cancer: The Next Generation

          The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.
            • Record: found
            • Abstract: found
            • Article: not found

            MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

            MicroRNAs (miRNAs) are small non-coding RNAs that can modulate mRNA expression. Insights into the roles of miRNAs in development and disease have led to the development of new therapeutic approaches that are based on miRNA mimics or agents that inhibit their functions (antimiRs), and the first such approaches have entered the clinic. This Review discusses the role of different miRNAs in cancer and other diseases, and provides an overview of current miRNA therapeutics in the clinic.
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer genome landscapes.

              Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer. For most cancer types, this landscape consists of a small number of "mountains" (genes altered in a high percentage of tumors) and a much larger number of "hills" (genes altered infrequently). To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or "drive" tumorigenesis. A typical tumor contains two to eight of these "driver gene" mutations; the remaining mutations are passengers that confer no selective growth advantage. Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance. A better understanding of these pathways is one of the most pressing needs in basic cancer research. Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.

                Author and article information

                Contributors
                +14164142692 , romaoleao@gmail.com
                joanadias_a@hotmail.com
                dave.lee@sickkids.ca
                ajcfigueiredo@gmail.com
                uri.tabori@sickkids.ca
                +351-289-800-100 , pjbranco@ualg.pt
                Journal
                J Biomed Sci
                J. Biomed. Sci
                Journal of Biomedical Science
                BioMed Central (London )
                1021-7770
                1423-0127
                12 March 2018
                12 March 2018
                2018
                : 25
                : 22
                Affiliations
                [1 ]ISNI 0000 0004 0474 0428, GRID grid.231844.8, Division of Urology, Department of Surgery Princess Margaret Cancer Centre, , University Health Network, ; 610 University Ave 3-130, Toronto, ON M5G 2M9 Canada
                [2 ]ISNI 0000 0001 2157 2938, GRID grid.17063.33, Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, , University of Toronto, ; 555 University Avenue, Toronto, ON M5G 1X8 Canada
                [3 ]ISNI 0000 0000 9511 4342, GRID grid.8051.c, Faculty of Medicine, , University of Coimbra, ; R. Larga, 3004-504 Coimbra, Coimbra Portugal
                [4 ]ISNI 0000000106861985, GRID grid.28911.33, Department of Urology, , Coimbra University Hospital, ; Coimbra, Portugal
                [5 ]ISNI 0000 0000 9693 350X, GRID grid.7157.4, Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, , University of Algarve, ; Edifício 2 – Ala Norte, 8005-139 Faro, Portugal
                [6 ]ISNI 0000 0000 9693 350X, GRID grid.7157.4, Centre for Biomedical Research (CBMR), , University of Algarve, ; Faro, Portugal
                [7 ]Algarve Biomedical Center, Campus Gambelas, Faro, Portugal
                [8 ]ISNI 0000 0004 0473 9646, GRID grid.42327.30, Division of Haematology/Oncology, , The Hospital for Sick Children, ; 555 University Avenue, Toronto, M5G 1X8ON Canada
                Author information
                http://orcid.org/0000-0003-3719-717X
                Article
                422
                10.1186/s12929-018-0422-8
                5846307
                29526163
                dc4ae9a4-0a00-4205-b965-602013f66350
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 6 November 2017
                : 21 February 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001871, Fundação para a Ciência e a Tecnologia;
                Award ID: SFRH/BD/102232/2014
                Award ID: PD/BD/105899/2014
                Award ID: UID/BIM/04773/2013
                Award Recipient :
                Categories
                Review
                Custom metadata
                © The Author(s) 2018

                Molecular medicine
                telomeres,telomerase,telomerase regulation,cancer biomarkers
                Molecular medicine
                telomeres, telomerase, telomerase regulation, cancer biomarkers

                Comments

                Comment on this article

                Related Documents Log